CAMP4 Therapeutics Corporation advances a pipeline of antisense oligonucleotide therapeutics designed to upregulate gene expression by modulating regulatory RNA elements. Its platform identifies candidates that increase production of specific proteins to treat genetic diseases caused by insufficient protein levels. The company develops these programmable RNA medicines with the goal of addressing a broad range of conditions through precise control of gene output.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 1.5 | — | -12.6 | — |
| Q3 2025 | 0.8 | — | -15.1 | — |
| Q4 2025 | 0.3 | — | -40.3 | — |
| Q1 2026 | 1.3 | — | -18.3 | — |
| Q2 2026 | 1.8 | 18.8% | -33.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Utah Medical Products, Inc. (UTMD), Apogee Acquisition Corp (AACP), SPACSphere Acquisition Corp. (SSAC), Ribbon Communications Inc. (RBBN), Peoples Bancorp of North Carolina, Inc. (PEBK), RGC Resources, Inc. (RGCO)